Author

Aditi Dey

Observed names: A C Dey, A Dey, A. Dey, Dey Aditi, Dey, A, Dey, Aditi

Institution: University College London

Observed institution: University College London

ORCID: 0009-0008-0402-1307

Observed ORCIDs: 0009-0008-0402-1307, 0000-0001-9813-2068

OpenAlex ID: A5102991862

Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress

2019 · Richard Burt, Aditi Dey, et al. · Blood · 259

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial

2016 · B Patel, A A Kirkwood, et al. · Leukemia · 125

Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

2018 · Vanessa Buatois, Zoë Johnson, et al. · Molecular Cancer Therapeutics · 117

Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity

2013 · Anna Castleton, Aditi Dey, et al. · Blood · 77

Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus

2020 · Sarah Aref, Anna Z. Castleton, et al. · Molecular Therapy · 40

Differential Cytopathology and Kinetics of Measles Oncolysis in Two Primary B-cell Malignancies Provides Mechanistic Insights

2011 · Bella Patel, Aditi Dey, et al. · Molecular Therapy · 30

Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology

2014 · Bella Patel, Aditi Dey, et al. · Blood · 27

Attenuated, Oncolytic, but Not Wild-Type Measles Virus Infection Has Pleiotropic Effects on Human Neutrophil Function

2011 · Yu Zhang, Bella Patel, et al. · The Journal of Immunology · 26

The Role of Neutrophils in Measles Virus–mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF

2015 · Aditi Dey, Yu Zhang, et al. · Molecular Therapy · 18

Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts

2024 · Richard J. Burt, Aditi Dey, et al. · Blood Advances · 11

Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14

2013 · Bella Patel, A Kirkwood, et al. · Blood · 9

B-Precursor Acute Lymphoblastic Leukaemia Causes Paracrine Senescence in Mesenchymal Stromal Cells to Subvert the Treatment Response in Adult Acute Lymphoblastic Leukaemia

2024 · Aditi Dey, Ruchi Kumari, et al. · Blood · 1

Acute Lymphoblastic Leukaemia (ALL) Cells and Commonly-Used Chemotherapy Drugs Can Induce Bone Marrow-Derived Mesenchymal Stromal Cells to Become Cancer Associated Fibroblasts (CAF), Leading to Enhanced ALL Proliferation and Treatment Resistance

2017 · Richard Burt, Aditi Dey, et al. · Blood · 1

The Role of the Bone Marrow Immune Niche in Preventing Relapse in Adult B-ALL Following Reduced Intensity Conditioning Allogeneic HSCT

2024 · Hermione E Allen, Andrew McIntyre, et al. · Blood

Mitochondrial dsRNA from B-Precursor Acute Lymphoblastic Leukemia Cells Induce Formation of Cancer Associated Fibroblast in the Bone Marrow Leading to Formation of a Chemoprotective Bone Marrow Niche

2023 · Aditi Dey, Richard Burt, et al. · Blood

Supplementary Figure S2 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

2023 · Vanessa Buatois, Zoë Johnson, et al.

Supplementary Table S2 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

2023 · Vanessa Buatois, Zoë Johnson, et al.

Supplementary Table S4 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

2023 · Vanessa Buatois, Zoë Johnson, et al.

Supplementary Table S5 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

2023 · Vanessa Buatois, Zoë Johnson, et al.

Video 1 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

2023 · Vanessa Buatois, Zoë Johnson, et al.

Supplementary Materials and Methods from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

2023 · Vanessa Buatois, Zoë Johnson, et al.

Supplementary Table S3 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

2023 · Vanessa Buatois, Zoë Johnson, et al.

Supplementary Table S1 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

2023 · Vanessa Buatois, Zoë Johnson, et al.

Video 2 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

2023 · Vanessa Buatois, Zoë Johnson, et al.

Supplementary Figure S1 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

2023 · Vanessa Buatois, Zoë Johnson, et al.

Works count: 45

Citation count: 741

H-index: 10

I10-index: 10